All articles tagged with #xenotransplantation
An American patient, Tim Andrews, lived 271 days with a transplanted pig kidney that maintained renal function without dialysis before receiving a human kidney transplant earlier this year, marking the longest dialysis-free survival after porcine kidney xenotransplantation and highlighting xenotransplantation as a potential way to address organ shortages by serving as a bridge or destination therapy.
Five patients at Massachusetts General Hospital have received pig kidneys grown in Yucatan miniature pigs engineered to reduce immune rejection. In three cases the kidneys functioned for more than eight months without rejection or dialysis; one patient later required a human donor kidney, but the pig-kidney period did not hinder overall transplant success. The trials are aimed at addressing the organ shortage and could serve as a bridge or destination therapy if long‑term safety is proven. The FDA has authorised an expanded trial of 33 patients across up to 10 US centers to begin next year, with plans to broaden to Japan and move toward marketing approval by 2029.
Doctors used a genetically engineered pig kidney (Wilma) to keep a 66-year-old man alive for 271 days—nine months—without dialysis, serving as a bridge to a human kidney transplant; the pig had 69 genome edits to reduce rejection and virus risk, and no pig pathogens were detected, but the kidney eventually failed and he later received a human donor kidney; this world-first case suggests xenotransplantation could alleviate the organ shortage but requires more trials.
A kidney from a genetically engineered pig kept Tim Andrews alive and functioning for 271 days—the longest xenotransplant on record—before it was removed. He then needed dialysis for 82 days until a human donor kidney was found. Published in Lancet, the case demonstrates xenotransplantation as a potential bridge to transplantation amid organ shortages, while also highlighting immune and vascular challenges that must be overcome.
Russia has launched a $26 billion state program, New Health Preservation Technologies, to push longevity through gene therapy, lab-grown organs, and xenotransplantation using mini-pigs, led by Putin allies Maria Vorontsova and Mikhail Kovalchuk. While officials tout breakthroughs, critics say peer-reviewed results are scarce and sanctions complicate Western collaboration, underscoring the regime’s desire to preserve power amid aging elite and rising mortality concerns.
A 53-year-old brain-dead man received a genetically modified pig liver and two pig kidneys. The organs functioned for about five days; the liver started bile production within 19 hours and kidney function normalized, suggesting feasibility. However, within 36 hours signs of rejection appeared as pig cells were replaced by human cells and inflammatory markers rose, indicating the need for immune-targeted therapies. The pig had six genome edits (three human genes added, three pig genes removed) to reduce rejection, marking a major step toward addressing organ shortages while highlighting ongoing challenges in long-term compatibility.
A Gothamist item claims Vladimir Putin is reportedly overseeing an effort to grow human replacement organs inside mini-pigs, a controversial claim tied to longevity research.
Putin leads a $26 billion longevity initiative focused on bio-printing tissues and growing human organs inside mini-pigs, with his daughter Maria Vorontsova and physicist Mikhail Kovalchuk at the helm; early milestones include bioprinted cartilage and a mouse thyroid, with a goal of human organ replacement by the decade's end, though some scientists question the lack of peer‑reviewed validation.
A 56-year-old man with liver failure was connected to an externally perfused, genetically modified pig liver to keep him alive while awaiting a human liver transplant. The pig organ, engineered with six genetic changes to reduce rejection, functioned as a bridge for a few days; the patient subsequently received a human liver and is recovering. Researchers note the need for more details and that results should be published in a peer-reviewed journal.
Nature highlights seven technologies set to shape 2026, from xenotransplantation using CRISPR-edited animal organs to reduce immune rejection, to AI-powered weather forecasting and climate modelling, a renewed push in next-generation nuclear power including small modular reactors and fusion, and advances in light-microscopy brain mapping alongside a massive Vera C. Rubin Observatory sky survey that will catalog billions of celestial objects over a decade—portending gains in medicine, energy, climate science, neuroscience, and astronomy.
Tim Andrews, one of the first recipients of a genetically modified pig kidney, has now received a human kidney after the pig organ failed, marking a historic step in xenotransplantation and illustrating its potential to address organ shortages and reduce dialysis. Researchers are refining immunosuppressive regimens and planning additional xenotransplants as trials move forward.
Tim Andrews—one of the first recipients of a genetically modified pig kidney—has now received a human kidney, becoming the first in that small group to cross from animal to human organ. The pig kidney lasted 271 days before rejection, after which he returned to dialysis; days later he underwent a near-perfectly matched human kidney transplant. The case highlights xenotransplantation as a potential bridge to address the organ shortage, with ongoing research to refine immunosuppression and improve graft survival and plans for additional trials.
Scientists are making progress in transplanting genetically modified pig kidneys into humans to address organ shortages, despite ethical debates about creating human-like animals and the risks involved. The article discusses the scientific advancements, ethical concerns about animal welfare and moral status, and the regulatory history surrounding the use of animal organs and chimeras.
A leading surgeon, Dr. Robert Montgomery, discusses the potential of pig organ transplants, which have been gene-edited to reduce rejection, as a promising solution to the organ shortage crisis, with initial trials showing positive results and the possibility of future improvements making pig organs potentially superior to human ones.
A 71-year-old man in China received the first successful genetically modified pig liver transplant, marking a significant milestone in xenotransplantation. Although the patient passed away after 171 days due to complications, the procedure demonstrated the potential of animal organs in human medicine, highlighting both progress and ongoing challenges in the field.